September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy

Patricio S. Espinosa/X

May 7, 2026, 16:53

Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy

Patricio S. Espinosa, Chief of Neurology and Institute Director at Espinosa Neuroscience Institute, shared a post on X:

”MYTH vs FACT: Amyloid Therapies & Anticoagulants

There is a common misconception that patients on anticoagulants (blood thinners) cannot receive amyloid-targeted therapies such as Kisunla (donanemab) and Leqembi (lecanemab).

MYTH:

Patients on anticoagulation are not candidates for amyloid therapies.

FACT:

With careful patient selection, strict adherence to protocols, and close monitoring, patients on anticoagulants can safely receive these therapies.

At Espinosa Neuroscience Institute, we have treated patients on anticoagulation with amyloid-targeted therapies without complications, by following:

Rigorous MRI screening protocols
Close monitoring for ARIA (Amyloid-Related Imaging Abnormalities)
Individualized risk–benefit assessment
Coordination of care across specialties

The key is not exclusion – it’s precision medicine.

These therapies are transforming how we treat mild cognitive impairment and early Alzheimer’s disease, and we should not deny patients access based on outdated assumptions.

Bottom line:

Anticoagulation is not an absolute contraindication – it requires expert management and protocol-driven care.”
Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy